Kaléo Promises Generic Naloxone Injector After Blistering Senate Pricing Report

Drug Industry Daily
A A
A month after a scathing congressional report hit Kaléo for hiking prices for its opioid antidote by 600 percent, the company announced it will release a lower-cost generic version of its auto-injector in 2019.

To View This Article:

Login

Subscribe To Drug Industry Daily